<DOC>
	<DOCNO>NCT00104806</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , arsenic trioxide , work different way stop growth cancer cell , either kill cell stop dividing . Cholecalciferol ( vitamin D ) may help cancer cell become normal cell . Giving arsenic trioxide together cholecalciferol ( vitamin D ) may kill cancer cell . PURPOSE : This phase II trial study well give arsenic trioxide together cholecalciferol ( vitamin D ) work treat patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Arsenic Trioxide Cholecalciferol ( Vitamin D ) Treating Patients With Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine complete response rate rate hematological improvement patient myelodysplastic syndrome treat arsenic trioxide cholecalciferol ( vitamin D ) . Secondary - Determine safety regimen patient . - Determine time progression acute myeloid leukemia , define blast ≥ 20 % , patient treat regimen . - Determine overall survival progression-free survival patient treat regimen . - Determine effect regimen bone marrow peripheral blood mononuclear cell apoptosis p21 protein expression patient . OUTLINE : This open-label , nonrandomized study . Patients receive oral cholecalciferol ( vitamin D ) * daily day 1-28 . Patients also receive arsenic trioxide IV 1-4 hour day 1-5 ( week 1 ) twice weekly 3 week ( week 2-4 ) course 1 twice weekly 4 week subsequent course . Courses repeat every 28 day 12 month absence disease progression unacceptable toxicity . NOTE : * Patients achieve complete hematologic response receive escalate dos cholecalciferol ( vitamin D ) 3 , 6 , 9 month therapy absence disease progression unacceptable toxicity . At completion study treatment , patient follow survival . PROJECTED ACCRUAL : A total 25-60 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis myelodysplastic syndrome ( MDS ) Bone marrow aspirate biopsy karyotyping perform within past 12 week PATIENT CHARACTERISTICS : Age Any age Performance status ECOG 02 Life expectancy More 6 month Hematopoietic Ferritin ≥ 50 ng/mL Folate ( serum and/or red blood cell ) normal Hepatic Not specify Renal Creatinine &lt; 2.0 mg/dL No history hypercalcemia Cardiovascular Absolute QT interval ≤ 460 msec EKG normal potassium magnesium level Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 week study participation Serum vitamin B_12 normal PRIOR CONCURRENT THERAPY : Biologic therapy Prior biologic therapy allow More 28 day since prior hematopoietic growth factor ( e.g. , filgrastim [ GCSF ] , sargramostim [ GMCSF ] , epoetin alfa ) MDS No concurrent hematopoietic growth factor ( e.g. , GCSF , GMCSF , epoetin alfa ) No concurrent interleukin11 Chemotherapy Prior chemotherapy allow Endocrine therapy Not specify Radiotherapy Prior radiotherapy allow Surgery Not specify Other More 28 day since prior therapy MDS except supportive therapy No concurrent cholecalciferol ( vitamin D ) analog , include topical therapy No concurrent vitamins supplement contain cholecalciferol ( vitamin D ) No concurrent therapy MDS</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>